Introducing Azifaith 250: Redefining the Standard in Pneumonia Treatment
We are proud to announce the launch of Azifaith 250, a next-generation azithromycin formulation engineered to deliver fast, effective, and dependable treatment for pneumonia and other serious respiratory infections.
Azifaith 250 belongs to the macrolide class of antibiotics, renowned for its broad-spectrum activity and exceptional tissue penetration. By inhibiting bacterial protein synthesis, Azifaith 250 provides rapid and sustained antibacterial action, ensuring both clinical cure and microbiological eradication.
Developed with a focus on patient needs and physician trust, Azifaith 250 offers:
- Powerful Efficacy Against Key Respiratory Pathogens
- Rapid Symptom Relief and Faster Recovery
- Excellent Tissue Penetration for Targeted Action
- High Patient Tolerability and Convenient Dosing
Key Features of Azifaith 250:
- Mechanism of Action: Binds to the 50S ribosomal subunit, inhibiting bacterial protein synthesis and halting bacterial growth.
- Indications: Treatment of community-acquired pneumonia (CAP) caused by susceptible strains of Streptococcus pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae, and other key pathogens.
- Administration: Convenient once-daily dosing for enhanced patient compliance.
- Manufactured to International GMP Standards: Ensuring purity, potency, and consistent therapeutic performance.
Faith in Healing. Strength in Innovation.
With Azifaith 250, we bring the power of trusted science and modern innovation together — delivering hope, health, and healing to every patient.
Now available.
Consult your healthcare provider about Azifaith 250 today.
